Related Experiment Videos
Clinician's guide to hepatitis C
1Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, MN 55905, USA.
Insights
Hepatitis C virus (HCV) infection is a widespread, chronic condition often diagnosed late, leading to severe liver disease. Early screening and evolving combination therapies offer improved outcomes for patients with this silent epidemic.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Hepatitis C virus (HCV) infection is a significant global health concern, frequently asymptomatic and leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- Mortality rates associated with chronic hepatitis C are projected to rise substantially, highlighting the urgent need for effective management and prevention strategies.
- Many infections remain undiagnosed due to a lack of awareness among both patients and healthcare providers, underscoring the importance of targeted screening.
Purpose of the Study:
- To emphasize the critical need for screening at-risk populations for Hepatitis C virus infection.
- To review current and emerging therapeutic strategies for managing chronic Hepatitis C.
- To highlight the disparity in public funding for Hepatitis C virus research compared to other viral infections like HIV.
Main Methods:
- Review of existing literature on Hepatitis C virus epidemiology, diagnosis, and treatment.
- Analysis of current therapeutic efficacy and projected advancements in antiviral agents.
- Comparison of funding models for viral disease research.
Main Results:
- Hepatitis C virus infection is common, chronic, and often asymptomatic, posing a significant risk for liver cirrhosis and cancer.
- Current interferon-based therapies offer limited sustained viral clearance (10-15%), with combination therapy (interferon and ribavirin) improving response rates to approximately 40%.
- Future treatments may involve novel agents like protease inhibitors and multi-drug regimens, similar to HIV therapy, but research funding remains a challenge.
Conclusions:
- Universal screening for Hepatitis C virus is recommended for all at-risk individuals, including those with transfusion history before 1992.
- Treatment outcomes for Hepatitis C virus are improving with combination therapies, and further advancements are anticipated.
- Increased public funding is crucial for accelerating the development of more effective Hepatitis C virus therapies and combating the growing burden of this disease.
Abstract:
Hepatitis C virus infection is common, often silent, and almost always chronic and can lead to cirrhosis and hepatocellular cancer. Deaths related to chronic hepatitis C are expected to increase dramatically in the future. Many cases of infection are asymptomatic and are undiagnosed because of a lack of recognition by patients and physicians. All patients currently or previously at risk of infection should undergo screening, including those who received blood transfusions before 1992. Interferon is the only effective therapy, but disappearance of virus is sustained in only 10 to 15% of patients. The combination of interferon and oral ribavirin therapy may increase the sustained response rate to about 40%. New agents such as hepatitis C virus-specific protease inhibitors may be available in the next 5 to 10 years, and treatment is evolving toward multiple-drug regimens analogous to those used for human immunodeficiency virus (HIV) infection. In contrast to public funding for drug development in HIV, such funding for hepatitis C has been limited.